CytomX Therapeutics, Inc. (CTMX)
3.215
-0.20
(-5.99%)
USD |
NASDAQ |
Aug 28, 16:00
3.22
0.00 (0.00%)
After-Hours: 20:00
CytomX Therapeutics Cash from Operations (Quarterly) : -18.07M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -18.07M |
| March 31, 2026 | -25.55M |
| December 31, 2025 | -23.24M |
| September 30, 2025 | -15.55M |
| June 30, 2025 | -15.75M |
| March 31, 2025 | -21.04M |
| December 31, 2024 | -19.91M |
| September 30, 2024 | -20.73M |
| June 30, 2024 | -19.55M |
| March 31, 2024 | -26.04M |
| December 31, 2023 | -21.96M |
| September 30, 2023 | -18.24M |
| June 30, 2023 | -25.18M |
| March 31, 2023 | 9.349M |
| December 31, 2022 | -1.393M |
| September 30, 2022 | -33.84M |
| June 30, 2022 | -34.24M |
| March 31, 2022 | -41.31M |
| December 31, 2021 | -31.19M |
| September 30, 2021 | -29.70M |
| June 30, 2021 | -28.20M |
| March 31, 2021 | -29.94M |
| December 31, 2020 | -17.43M |
| Date | Value |
|---|---|
| September 30, 2020 | -24.68M |
| June 30, 2020 | 97.10M |
| March 31, 2020 | -49.74M |
| December 31, 2019 | -29.48M |
| September 30, 2019 | -23.32M |
| June 30, 2019 | -48.65M |
| March 31, 2019 | -39.03M |
| December 31, 2018 | -28.74M |
| September 30, 2018 | -5.551M |
| June 30, 2018 | -26.62M |
| March 31, 2018 | -14.61M |
| December 31, 2017 | 22.00M |
| September 30, 2017 | -5.738M |
| June 30, 2017 | 173.20M |
| March 31, 2017 | -19.09M |
| December 31, 2016 | 1.936M |
| September 30, 2016 | -14.18M |
| June 30, 2016 | 15.75M |
| March 31, 2016 | -5.54M |
| December 31, 2015 | -8.169M |
| September 30, 2015 | -7.766M |
| June 30, 2015 | -6.111M |
| March 31, 2015 | -5.369M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 813.00M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 5.953M |
| Cash from Financing (Quarterly) | 0.511M |
| Free Cash Flow | -82.48M |
| Free Cash Flow Per Share (Quarterly) | -0.0825 |
| Free Cash Flow to Equity (Quarterly) | -20.92M |
| Free Cash Flow to Firm (Quarterly) | -18.07M |
| Free Cash Flow Yield | -14.03% |